Skip to main content

Table 2 TFAM scores for alignments of human sense and antisense mt tRNA sequences with groups of tRNAs with known function.

From: Undetected antisense tRNAs in mitochondrial genomes?

tRNA

A

C

D

E

F

G

H

I

K

L

M

N

P

Q

R

S

T

V

W

Y

Sense

                    

Ala, 11

-19

-17

-19

-22

-30

1

-10

-57

0

-48

-21

-7

-4

5

-5

-79

-3

-3

3

-34

Cys, 1**

-42

15

8

5

-5

-1

-2

-34

-5

-33

-13

8

0

4

10

-69

-8

-14

18

-26

Asp, 9

-39

-3

-13

-8

-33

9

-12

-29

-7

-66

-29

-19

-12

-15

-8

-70

-15

-2

-2

-44

Glu, 6

-34

-19

-17

-10

-7

-16

-16

-38

-7

-46

-30

-8

-32

0

-8

-82

-11

-11

1

-42

Phe, 2**

-35

-12

-15

-15

7

-7

-9

-15

-7

-48

15

-12

-12

-22

5

-56

10

-6

-14

-26

Gly, 5**

-35

1

-14

8

-8

4

-4

-42

9

-46

-31

3

-27

9

-2

-75

7

-1

7

-38

His, 1**

-27

-13

-16

-3

-20

15

13

-53

-17

-55

-22

-14

-26

-6

-3

-57

-12

-17

-13

-28

Ile, 14

-28

-9

-17

-19

-16

3

-6

-23

-24

-46

-3

-22

-9

-21

-13

-46

-13

-1

-7

-35

Lys, 0**

-10

1

-4

-8

-1

17

0

-29

19

-49

0

2

1

-10

11

-70

9

9

2

-31

LeuUUR, 17**

-49

-18

-38

-21

-10

-29

-20

-43

-23

-48

-11

-30

-25

-32

-17

-61

-21

-19

-32

-38

Leu CUN, 16**

-46

6

-19

-7

-4

-8

-2

-32

-10

-34

-21

-12

-17

14

-3

-72

-11

-9

1

-45

Met, 0**

-37

-6

-16

-19

-11

-22

-13

-36

-10

-55

1

-8

-21

-3

-11

-66

-23

-11

1

-32

Asn, 0**

-34

-23

-4

-28

-35

-21

-2

-25

-11

-77

-21

4

-10

-8

0

-80

-23

-13

-14

-55

Pro, 1**

-23

-37

-24

-30

-25

15

-8

-31

-9

-45

-26

-25

8

-10

-1

-86

-16

2

4

-61

Gln, 0**

-42

-22

-27

-17

-29

-17

-1

-69

-26

-33

-30

-15

-14

2

-17

-79

-15

-35

-4

-52

Arg, 5**

-25

-6

-15

-12

-13

3

-7

-33

-3

-53

-16

-3

-8

28

-5

-60

-9

-9

9

-31

SerAGY, 19**

1

38

18

21

21

37

37

12

45

-19

30

36

30

36

28

-31

30

35

34

9

SerUCN, 17**

-28

-11

-16

-13

-22

-20

-15

-53

-8

-51

-17

-4

-15

-8

-6

-40

-16

-11

-2

-7

Thr, 2**

-27

-8

-4

4

-6

6

-8

-25

0

-38

-15

-2

-18

-4

4

-65

5

-13

11

-36

Trp, 0**

-12

6

-6

3

-4

16

-7

-34

6

-49

-4

0

-8

6

8

-38

-2

1

27

-32

Tyr, 16**

-24

-6

-19

-25

-5

-10

-12

-33

-9

-46

-7

-10

-19

-25

-10

-51

-4

-7

-15

-28

Val, 2**

-18

-10

-17

-21

-16

4

-13

-30

-14

-47

-18

-13

-6

-8

-7

-82

-5

-4

-2

-44

Antisense

A

C

D

E

F

G

H

I

K

L

M

N

P

Q

R

S

T

V

W

Y

Cys, 0**

23

53

26

41

29

35

46

-11

38

-27

20

33

36

42

29

-41

24

40

46

13

Ala, 16**

-11

34

17

32

27

15

29

-28

28

-18

3

18

3

20

18

-27

14

11

15

3

Val, 2**

-13

14

10

7

-1

40

10

-26

-1

-55

-5

3

2

6

-1

-40

5

18

19

-21

Phe, 1**

-14

38

8

5

36

-2

21

1

23

-31

12

28

4

20

21

-39

20

18

33

-8

Glu, 5**

-2

31

35

35

24

27

58

-22

42

46

2

30

24

54

16

5

19

31

41

31

SerUCN, 19**

-25

16

4

8

12

-5

8

-31

15

-34

-11

23

-11

6

-1

-61

16

2

3

-18

Val, 2**

0

27

18

21

21

23

35

-2

29

-24

20

15

20

32

21

-22

10

31

31

16

Asp, 7

-8

40

23

31

13

27

38

-16

23

-28

11

22

21

33

14

-9

7

39

29

17

Phe, 8

-33

20

21

-2

10

1

14

-35

11

-2

-16

16

-6

20

-3

-44

2

11

26

-4

Stop, 20**

-19

40

26

12

26

5

30

-30

17

-1

5

36

12

25

7

-13

11

11

29

23

LeuUUR, 17**

-27

10

-1

14

6

-10

-1

-38

19

-29

-12

21

6

15

6

-61

3

4

7

-19

His, 4**

-13

18

12

5

10

13

27

-8

13

-13

-5

9

28

24

7

-36

7

16

15

-12

Val, 6

-15

30

18

14

8

27

34

-22

7

-29

3

27

24

38

8

-47

9

19

19

-11

Trp, 4**

-4

47

23

41

23

23

39

-15

33

-21

19

21

27

39

28

-27

14

25

38

23

LeuUUR, 15**

-22

25

-14

-4

15

6

16

-42

11

-9

3

8

-1

11

-4

-26

4

3

20

-5

SerUCN, 20**

0

36

13

5

36

19

32

-17

25

-26

13

30

18

35

15

-34

32

21

37

12

Ala, 12

24

39

32

18

36

28

48

12

25

-14

22

34

49

34

21

-35

31

41

37

0

Trp, 4**

-16

20

2

5

2

-5

17

-47

19

-20

-14

11

10

25

-5

-29

-5

7

12

6

Cys, 0**

-14

29

17

22

1

-7

14

-15

11

-41

-13

14

2

26

16

-37

1

10

24

-3

Tyr, 12

-13

4

8

-7

9

6

19

-31

10

-36

-6

21

-12

12

-2

-50

8

9

2

-5

SerUCN, 19**

-12

16

-6

3

0

17

9

-41

1

-32

-17

3

1

17

-7

-43

9

10

1

-7

Val, 3**

-16

22

12

14

2

-5

18

-17

18

-33

-5

14

15

35

0

-18

-6

18

22

9

  1. Each row is for a target tRNA sequence, indicated by its three letter cognate abbreviation, followed by the number of scores higher than the score of the cognate predicted by the anticodon. Columns are headed by the standard one letter abbreviation of cognate amino acids, indicating the known tRNA functional groups. Scores are alignment quality (here interpreted as proportional to probability of acylation of the target tRNA sequence by the cognate of the 'standard' tRNA group used by TFAM (http://tfam.lcb.uu.se/[53])) between the target tRNA sequence and the sequences used by TFAM as the reference group of tRNAs with known function. Negative and positive scores indicate alignment quality lower and higher than for random sequences, respectively. Bold scores indicate the amino acid matching the target tRNA's anticodon according to the genetic code. Antisense tRNAs are ordered according to their matching sense tRNA. Asterisks indicate two tailed statistical significance at P < 0.05 according to a binomial distribution for misacylation potentials.